A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

3,307

Participants

Timeline

Start Date

June 17, 2020

Primary Completion Date

February 21, 2023

Study Completion Date

February 21, 2023

Conditions
COVID-19
Interventions
DRUG

LY3819253

Administered IV

DRUG

LY3832479

Administered IV

DRUG

LY3853113

Administered IV

DRUG

Placebo

Administered IV

Trial Locations (12)

28112

Monroe Biomed Research, Monroe

30291

Rophe Adult and Pediatric Medicine, Union City

33184

Bio-Medical Research, LLC, Miami

39069

Sky Clinical Prime and Health Wellness Clinic, Fayette

39157

Sky Clin Resch - Quinn HC, Ridgeland

48201

Childrens Hospital of Michigan, Detroit

48706

Great Lakes Research Group, Inc., Bay City

75246

B S & W Med Center, Dallas

78215

Sun Research Institute, San Antonio

90277

Clinnova Research - Redondo Beach, Redondo Beach

02114

Massachusetts General Hospital, Boston

01655

U of MA Mem Med Ctr, Worcester

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AbCellera Biologics Inc.

INDUSTRY

collaborator

Shanghai Junshi Bioscience Co., Ltd.

OTHER

lead

Eli Lilly and Company

INDUSTRY